<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">30343150</PMID>
      <DateCompleted>
        <Year>2019</Year>
        <Month>06</Month>
        <Day>10</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2020</Year>
        <Month>07</Month>
        <Day>24</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1878-5875</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>105</Volume>
            <PubDate>
              <Year>2018</Year>
              <Month>Dec</Month>
            </PubDate>
          </JournalIssue>
          <Title>The international journal of biochemistry &amp; cell biology</Title>
          <ISOAbbreviation>Int J Biochem Cell Biol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Therapeutic potential of targeting the Eph/ephrin signaling complex.</ArticleTitle>
        <Pagination>
          <StartPage>123</StartPage>
          <EndPage>133</EndPage>
          <MedlinePgn>123-133</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.biocel.2018.10.006</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S1357-2725(18)30230-9</ELocationID>
        <Abstract>
          <AbstractText>The Eph-ephrin signaling pathway mediates developmental processes and the proper functioning of the adult human body. This distinctive bidirectional signaling pathway includes a canonical downstream signal cascade inside the Eph-bearing cells, as well as a reverse signaling in the ephrin-bearing cells. The signaling is terminated by ADAM metalloproteinase cleavage, internalization, and degradation of the Eph/ephrin complexes. Consequently, the Eph-ephrin-ADAM signaling cascade has emerged as a key target with immense therapeutic potential particularly in the context of cancer. An interesting twist was brought forth by the emergence of ephrins as the entry receptors for the pathological Henipaviruses, which has spurred new studies to target the viral entry. The availability of high-resolution structures of the multi-modular Eph receptors in complexes with ephrins and other binding partners, such as peptides, small molecule inhibitors and antibodies, offers a wealth of information for the structure-guided development of therapeutic intervention. Furthermore, genomic data mining of Eph mutants involved in cancer provides information for targeted drug development. In this review we summarize the distinct avenues for targeting the Eph-ephrin signaling pathway, including its termination by ADAM proteinases. We highlight the latest developments in Eph-related pharmacology in the context of Eph-ephrin-ADAM-based antibodies and small molecules. Finally, the future prospects of genomics- and proteomics-based medicine are discussed.</AbstractText>
          <CopyrightInformation>Copyright © 2018 Elsevier Ltd. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Saha</LastName>
            <ForeName>Nayanendu</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Sloan-Kettering Institute for Cancer Research, Structural Biology Program, 1275 York Avenue, New York, NY 10065, United States.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Robev</LastName>
            <ForeName>Dorothea</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Sloan-Kettering Institute for Cancer Research, Structural Biology Program, 1275 York Avenue, New York, NY 10065, United States.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mason</LastName>
            <ForeName>Emilia O</ForeName>
            <Initials>EO</Initials>
            <AffiliationInfo>
              <Affiliation>Sloan-Kettering Institute for Cancer Research, Structural Biology Program, 1275 York Avenue, New York, NY 10065, United States.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Himanen</LastName>
            <ForeName>Juha P</ForeName>
            <Initials>JP</Initials>
            <AffiliationInfo>
              <Affiliation>Sloan-Kettering Institute for Cancer Research, Structural Biology Program, 1275 York Avenue, New York, NY 10065, United States. Electronic address: himanenj@mskcc.org.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nikolov</LastName>
            <ForeName>Dimitar B</ForeName>
            <Initials>DB</Initials>
            <AffiliationInfo>
              <Affiliation>Sloan-Kettering Institute for Cancer Research, Structural Biology Program, 1275 York Avenue, New York, NY 10065, United States.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>P30 CA008748</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 NS038486</GrantID>
            <Acronym>NS</Acronym>
            <Agency>NINDS NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 NS096956</GrantID>
            <Acronym>NS</Acronym>
            <Agency>NINDS NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R21 CA185930</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2018</Year>
          <Month>10</Month>
          <Day>19</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Int J Biochem Cell Biol</MedlineTA>
        <NlmUniqueID>9508482</NlmUniqueID>
        <ISSNLinking>1357-2725</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000906">Antibodies</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D036342">Ephrins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.10.1</RegistryNumber>
          <NameOfSubstance UI="D036081">Receptors, Eph Family</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.4.24.-</RegistryNumber>
          <NameOfSubstance UI="D051722">ADAM Proteins</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D051722" MajorTopicYN="N">ADAM Proteins</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000906" MajorTopicYN="N">Antibodies</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001665" MajorTopicYN="N">Binding Sites</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000076722" MajorTopicYN="N">Drug Development</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D036342" MajorTopicYN="N">Ephrins</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008954" MajorTopicYN="N">Models, Biological</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008958" MajorTopicYN="N">Models, Molecular</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D036081" MajorTopicYN="N">Receptors, Eph Family</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">ADAM proteinase</Keyword>
        <Keyword MajorTopicYN="Y">Antibody drug</Keyword>
        <Keyword MajorTopicYN="Y">Eph receptor</Keyword>
        <Keyword MajorTopicYN="Y">Eph-specific peptide</Keyword>
        <Keyword MajorTopicYN="Y">Small molecule inhibitor</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2018</Year>
          <Month>8</Month>
          <Day>1</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2018</Year>
          <Month>10</Month>
          <Day>9</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2018</Year>
          <Month>10</Month>
          <Day>16</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2018</Year>
          <Month>10</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2019</Year>
          <Month>6</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2018</Year>
          <Month>10</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">30343150</ArticleId>
        <ArticleId IdType="mid">NIHMS1512638</ArticleId>
        <ArticleId IdType="pmc">PMC6457248</ArticleId>
        <ArticleId IdType="doi">10.1016/j.biocel.2018.10.006</ArticleId>
        <ArticleId IdType="pii">S1357-2725(18)30230-9</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Abengozar MA, de Frutos S, Ferreiro S, Soriano J, Perez-Martinez M, Olmeda D, Marenchino M, Canamero M, Ortega S, Megias D, Rodriguez A and Martinez-Torrecuadrada JL (2012) Blocking ephrinB2 with highly specific antibodies inhibits angiogenesis, lymphangiogenesis, and tumor growth. Blood
119:4565–4576.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22446484</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Adams RH (2003) Molecular control of arterial-venous blood vessel identity. J Anat
202:105–112.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1571062</ArticleId>
            <ArticleId IdType="pubmed">12587925</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Amero P, Esposito CL, Rienzo A, Moscato F, Catuogno S and de Franciscis V (2016) Identification of an Interfering Ligand Aptamer for EphB2/3 Receptors. Nucleic Acid Ther
26:102–110.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26824783</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Annunziata CM, Kohn EC, LoRusso P, Houston ND, Coleman RL, Buzoianu M, Robbie G and Lechleider R (2013) Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumors. Investigational new drugs
31:77–84.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3553417</ArticleId>
            <ArticleId IdType="pubmed">22370972</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Anonymous (2013) Nipah encephalitis, human - Bangladesh (05), in Pro-med, International Society for Infectious Diseases.</Citation>
        </Reference>
        <Reference>
          <Citation>Atapattu L, Lackmann M and Janes PW (2014) The role of proteases in regulating Eph/ephrin signaling. Cell adhesion &amp; migration
8:294–307.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4594553</ArticleId>
            <ArticleId IdType="pubmed">25482632</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Atapattu L, Saha N, Llerena C, Vail ME, Scott AM, Nikolov DB, Lackmann M and Janes PW (2012) Antibodies binding the ADAM10 substrate recognition domain inhibit Eph function. Journal of cell science
125:6084–6093.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3585520</ArticleId>
            <ArticleId IdType="pubmed">23108669</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Attwood BK, Bourgognon JM, Patel S, Mucha M, Schiavon E, Skrzypiec AE, Young KW, Shiosaka S, Korostynski M, Piechota M, Przewlocki R and Pawlak R (2011) Neuropsin cleaves EphB2 in the amygdala to control anxiety. Nature
473:372–375.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3145099</ArticleId>
            <ArticleId IdType="pubmed">21508957</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barile E, Wang S, Das SK, Noberini R, Dahl R, Stebbins JL, Pasquale EB, Fisher PB and Pellecchia M (2014) Design, synthesis and bioevaluation of an EphA2 receptor-based targeted delivery system. ChemMedChem
9:1403–1412.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4082471</ArticleId>
            <ArticleId IdType="pubmed">24677792</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barquilla A and Pasquale EB (2015) Eph receptors and ephrins: therapeutic opportunities. Annual review of pharmacology and toxicology
55:465–487.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4388660</ArticleId>
            <ArticleId IdType="pubmed">25292427</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barton WA, Himanen JP, Antipenko A and Nikolov DB (2004) Structures of axon guidance molecules and their neuronal receptors. Advances in protein chemistry
68:65–106.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15500859</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Biao-xue R, Xi-guang C, Shuan-ying Y, Wei L and Zong-juan M (2011) EphA2-dependent molecular targeting therapy for malignant tumors. Current cancer drug targets
11:1082–1097.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21933105</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bossart KN, Fusco DL and Broder CC (2013) Paramyxovirus Entry, in Viral Entry into Host Cells (Pöhlmann S and Simmons G eds) pp 95–127, Landes Bioscience and Springer Science+Business Media, Austin, TX</Citation>
        </Reference>
        <Reference>
          <Citation>Bossart KN, Geisbert TW, Feldmann H, Zhu Z, Feldmann F, Geisbert JB, Yan L, Feng YR, Brining D, Scott D, Wang Y, Dimitrov AS, Callison J, Chan YP, Hickey AC, Dimitrov DS, Broder CC and Rockx B (2011) A neutralizing human monoclonal antibody protects african green monkeys from hendra virus challenge. Science translational medicine
3:105ra103.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3313625</ArticleId>
            <ArticleId IdType="pubmed">22013123</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bossart KN, Zhu Z, Middleton D, Klippel J, Crameri G, Bingham J, McEachern JA, Green D, Hancock TJ, Chan YP, Hickey AC, Dimitrov DS, Wang LF and Broder CC (2009) A neutralizing human monoclonal antibody protects against lethal disease in a new ferret model of acute nipah virus infection. PLoS pathogens
5:e1000642.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2765826</ArticleId>
            <ArticleId IdType="pubmed">19888339</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bowden TA, Aricescu AR, Gilbert RJ, Grimes JM, Jones EY and Stuart DI (2008a) Structural basis of Nipah and Hendra virus attachment to their cell-surface receptor ephrin-B2. Nature structural &amp; molecular biology
15:567–572.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18488039</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bowden TA, Crispin M, Harvey DJ, Aricescu AR, Grimes JM, Jones EY and Stuart DI (2008b) Crystal Structure and Carbohydrate Analysis of Nipah Virus Attachment Glycoprotein: A Template for Antiviral and Vaccine Design. J Virol.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2583688</ArticleId>
            <ArticleId IdType="pubmed">18815311</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Boyd AW, Bartlett PF and Lackmann M (2014) Therapeutic targeting of EPH receptors and their ligands. Nature reviews Drug discovery
13:39–62.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24378802</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Boyd AW and Lackmann M (2001) Signals from Eph and ephrin proteins: a developmental tool kit. Science's STKE : signal transduction knowledge environment
2001:re20.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11741094</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brantley-Sieders DM and Chen J (2004) Eph receptor tyrosine kinases in angiogenesis: from development to disease. Angiogenesis
7:17–28.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15302992</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brantley DM, Cheng N, Thompson EJ, Lin Q, Brekken RA, Thorpe PE, Muraoka RS, Cerretti DP, Pozzi A, Jackson D, Lin C and Chen J (2002) Soluble Eph A receptors inhibit tumor angiogenesis and progression in vivo. Oncogene
21:7011–7026.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12370823</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Broder CC (2010) Therapeutics and Vaccines against Hendra and Nipah Viruses, in New Generation Vaccines (Levine MM, Dougan G, Good MF, Liu MA, Nabel GJ, Nataro JP and Rappuoli R eds) pp 885–894, Informa Healthcare; 
USA, New York.</Citation>
        </Reference>
        <Reference>
          <Citation>Broder CC (2013) Passive Immunization and Active Vaccination against Hendra and Nipah Viruses. Developments in biologicals
135:125–138.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23689890</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Broder CC, Geisbert TW, Xu K, Nikolov DB, Wang LF, Middleton D, Pallister J and Bossart KN (2012) Immunization strategies against henipaviruses. Current topics in microbiology and immunology
359:197–223.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4465348</ArticleId>
            <ArticleId IdType="pubmed">22481140</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Broder CC, Xu K, Nikolov DB, Zhu Z, Dimitrov DS, Middleton D, Pallister J, Geisbert TW, Bossart KN and Wang LF (2013) A treatment for and vaccine against the deadly Hendra and Nipah viruses. Antiviral research
100:8–13.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4418552</ArticleId>
            <ArticleId IdType="pubmed">23838047</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Castelli R, Tognolini M, Vacondio F, Incerti M, Pala D, Callegari D, Bertoni S, Giorgio C, Hassan-Mohamed I, Zanotti I, Bugatti A, Rusnati M, Festuccia C, Rivara S, Barocelli E, Mor M and Lodola A (2015) Delta(5)-Cholenoyl-amino acids as selective and orally available antagonists of the Eph-ephrin system. European journal of medicinal chemistry
103:312–324.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26363867</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cazzamalli S, Dal Corso A, Widmayer F and Neri D (2018) Chemically Defined Antibody- and Small Molecule-Drug Conjugates for in Vivo Tumor Targeting Applications: A Comparative Analysis. Journal of the American Chemical Society
140:1617–1621.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5844464</ArticleId>
            <ArticleId IdType="pubmed">29342352</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, Antipin Y, Reva B, Goldberg AP, Sander C and Schultz N (2012) The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer discovery
2:401–404.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3956037</ArticleId>
            <ArticleId IdType="pubmed">22588877</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Charmsaz S, Beckett K, Smith FM, Bruedigam C, Moore AS, Al-Ejeh F, Lane SW and Boyd AW (2015) EphA2 Is a Therapy Target in EphA2-Positive Leukemias but Is Not Essential for Normal Hematopoiesis or Leukemia. PloS one
10:e0130692.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4470658</ArticleId>
            <ArticleId IdType="pubmed">26083390</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Charmsaz S and Boyd AW (2017) Eph receptors as oncotargets. Oncotarget
8:81727–81728.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5669840</ArticleId>
            <ArticleId IdType="pubmed">29137214</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Charmsaz S, Scott AM and Boyd AW (2017) Targeted therapies in hematological malignancies using therapeutic monoclonal antibodies against Eph family receptors. Exp Hematol
54:31–39.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28751189</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chaudhari A, Mahfouz M, Fialho AM, Yamada T, Granja AT, Zhu Y, Hashimoto W, Schlarb-Ridley B, Cho W, Das Gupta TK and Chakrabarty AM (2007) Cupredoxin-cancer interrelationship: azurin binding with EphB2, interference in EphB2 tyrosine phosphorylation, and inhibition of cancer growth. Biochemistry
46:1799–1810.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17249693</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen Y, Zhang H and Zhang Y (2017) Targeting receptor tyrosine kinase EphB4 in cancer therapy. Semin Cancer Biol.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28993206</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cheng PF, Dummer R and Levesque MP (2015) Data mining The Cancer Genome Atlas in the era of precision cancer medicine. Swiss medical weekly
145:w14183.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26375999</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chrencik JE, Brooun A, Recht MI, Kraus ML, Koolpe M, Kolatkar AR, Bruce RH, Martiny-Baron G, Widmer H, Pasquale EB and Kuhn P (2006) Structure and thermodynamic characterization of the EphB4/Ephrin-B2 antagonist peptide complex reveals the determinants for receptor specificity. Structure
14:321–330.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16472751</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Colgrave ML, Snelling HJ, Shiell BJ, Feng YR, Chan YP, Bossart KN, Xu K, Nikolov DB, Broder CC and Michalski WP (2011) Site occupancy and glycan compositional analysis of two soluble recombinant forms of the attachment glycoprotein of Hendra virus. Glycobiology
22:572–584.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3287018</ArticleId>
            <ArticleId IdType="pubmed">22171062</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Craik DJ, Fairlie DP, Liras S and Price D (2013) The future of peptide-based drugs. Chemical biology &amp; drug design
81:136–147.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23253135</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Damelin M, Bankovich A, Park A, Aguilar J, Anderson W, Santaguida M, Aujay M, Fong S, Khandke K, Pulito V, Ernstoff E, Escarpe P, Bernstein J, Pysz M, Zhong W, Upeslacis E, Lucas J, Lucas J, Nichols T, Loving K, Foord O, Hampl J, Stull R, Barletta F, Falahatpisheh H, Sapra P, Gerber HP and Dylla SJ (2015) Anti-EFNA4 Calicheamicin Conjugates Effectively Target Triple-Negative Breast and Ovarian Tumor-Initiating Cells to Result in Sustained Tumor Regressions. Clin Cancer Res
21:4165–4173.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26015513</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>DasGupta S, Murumkar PR, Giridhar R and Yadav MR (2009) Current perspective of TACE inhibitors: a review. Bioorganic &amp; medicinal chemistry
17:444–459.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19095454</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>DeVeale B, Bausch-Fluck D, Seaberg R, Runciman S, Akbarian V, Karpowicz P, Yoon C, Song H, Leeder R, Zandstra PW, Wollscheid B and van der Kooy D (2014) Surfaceome profiling reveals regulators of neural stem cell function. Stem cells
32:258–268.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24023036</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dines M and Lamprecht R (2014) EphrinA4 mimetic peptide targeted to EphA binding site impairs the formation of long-term fear memory in lateral amygdala. Translational psychiatry
4:e450.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4203006</ArticleId>
            <ArticleId IdType="pubmed">25268254</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dobrzanski P, Hunter K, Jones-Bolin S, Chang H, Robinson C, Pritchard S, Zhao H and Ruggeri B (2004) Antiangiogenic and antitumor efficacy of EphA2 receptor antagonist. Cancer research
64:910–919.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14871820</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dong J, Zhao H, Zhou T, Spiliotopoulos D, Rajendran C, Li XD, Huang D and Caflisch A (2015) Structural Analysis of the Binding of Type I, I1/2, and II Inhibitors to Eph Tyrosine Kinases. ACS medicinal chemistry letters
6:79–83.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4291711</ArticleId>
            <ArticleId IdType="pubmed">25589935</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Drag M and Salvesen GS (2010) Emerging principles in protease-based drug discovery. Nature reviews Drug discovery
9:690–701.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2974563</ArticleId>
            <ArticleId IdType="pubmed">20811381</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Duan S, Wu A, Chen Z, Yang Y, Liu L and Shu Q (2017) MiR-204 Regulates Cell Proliferation and Invasion by Targeting EphB2 in Human Cervical Cancer. Oncol Res.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7844721</ArticleId>
            <ArticleId IdType="pubmed">28800788</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dutch RE (2010) Entry and fusion of emerging paramyxoviruses. PLoS Pathog
6:e1000881.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2891828</ArticleId>
            <ArticleId IdType="pubmed">20585631</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dutta P, Siddiqui A, Botlani M and Varma S (2016) Stimulation of Nipah Fusion: Small Intradomain Changes Trigger Extensive Interdomain Rearrangements. Biophys J
111:1621–1630.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5071607</ArticleId>
            <ArticleId IdType="pubmed">27760350</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eaton BT, Broder CC, Middleton D and Wang LF (2006) Hendra and Nipah viruses: different and dangerous. Nat Rev Microbiol
4:23–35.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7097447</ArticleId>
            <ArticleId IdType="pubmed">16357858</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eaton BT, Wright PJ, Wang LF, Sergeyev O, Michalski WP, Bossart KN and Broder CC (2004) Henipaviruses: recent observations on regulation of transcription and the nature of the cell receptor. Archives of virology Supplementum:122–131.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15119767</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Egea J and Klein R (2007) Bidirectional Eph-ephrin signaling during axon guidance. Trends in cell biology
17:230–238.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17420126</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eriksson O, Ramstrom M, Hornaeus K, Bergquist J, Mokhtari D and Siegbahn A (2014) The Eph tyrosine kinase receptors EphB2 and EphA2 are novel proteolytic substrates of tissue factor/coagulation factor VIIa. The Journal of biological chemistry
289:32379–32391.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4239594</ArticleId>
            <ArticleId IdType="pubmed">25281742</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fabes J, Anderson P, Brennan C and Bolsover S (2007) Regeneration-enhancing effects of EphA4 blocking peptide following corticospinal tract injury in adult rat spinal cord. The European journal of neuroscience
26:2496–2505.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17970742</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ferluga S, Tome CM, Herpai DM, D'Agostino R and Debinski W (2016) Simultaneous targeting of Eph receptors in glioblastoma. Oncotarget
7:59860–59876.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5312354</ArticleId>
            <ArticleId IdType="pubmed">27494882</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Festuccia C, Gravina GL, Giorgio C, Mancini A, Pellegrini C, Colapietro A, Delle Monache S, Maturo MG, Sferra R, Chiodelli P, Rusnati M, Cantoni A, Castelli R, Vacondio F, Lodola A and Tognolini M (2018) UniPR1331, a small molecule targeting Eph/ephrin interaction, prolongs survival in glioblastoma and potentiates the effect of antiangiogenic therapy in mice. Oncotarget
9:24347–24363.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5966254</ArticleId>
            <ArticleId IdType="pubmed">29849945</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Field H, Crameri G, Kung NY and Wang LF (2012) Ecological aspects of hendra virus. Current topics in microbiology and immunology
359:11–23.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22476530</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Field HE (2016) Hendra virus ecology and transmission. Current opinion in virology
16:120–125.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26978066</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fosgerau K and Hoffmann T (2015) Peptide therapeutics: current status and future directions. Drug discovery today
20:122–128.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25450771</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fridy PC, Li Y, Keegan S, Thompson MK, Nudelman I, Scheid JF, Oeffinger M, Nussenzweig MC, Fenyo D, Chait BT and Rout MP (2014) A robust pipeline for rapid production of versatile nanobody repertoires. Nature methods
11:1253–1260.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4272012</ArticleId>
            <ArticleId IdType="pubmed">25362362</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fu AK, Hung KW, Huang H, Gu S, Shen Y, Cheng EY, Ip FC, Huang X, Fu WY and Ip NY (2014) Blockade of EphA4 signaling ameliorates hippocampal synaptic dysfunctions in mouse models of Alzheimer's disease. Proc Natl Acad Sci U S A
111:9959–9964.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4103318</ArticleId>
            <ArticleId IdType="pubmed">24958880</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Galimberti I, Bednarek E, Donato F and Caroni P (2010) EphA4 signaling in juveniles establishes topographic specificity of structural plasticity in the hippocampus. Neuron
65:627–642.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20223199</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, Cerami E, Sander C and Schultz N (2013) Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Science signaling
6:pl1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4160307</ArticleId>
            <ArticleId IdType="pubmed">23550210</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Giorgio C, Hassan Mohamed I, Flammini L, Barocelli E, Incerti M, Lodola A and Tognolini M (2011) Lithocholic acid is an Eph-ephrin ligand interfering with Eph-kinase activation. PloS one
6:e18128.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3068151</ArticleId>
            <ArticleId IdType="pubmed">21479221</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Giorgio C, Incerti M, Corrado M, Rusnati M, Chiodelli P, Russo S, Callegari D, Ferlenghi F, Ballabeni V, Barocelli E, Lodola A and Tognolini M (2018) Pharmacological evaluation of new bioavailable small molecules targeting Eph/ephrin interaction. Biochemical pharmacology
147:21–29.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29129483</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Giorgio C, Russo S, Incerti M, Bugatti A, Vacondio F, Barocelli E, Mor M, Pala D, Hassan-Mohamed I, Gioiello A, Rusnati M, Lodola A and Tognolini M (2016) Biochemical characterization of EphA2 antagonists with improved physico-chemical properties by cell-based assays and surface plasmon resonance analysis. Biochemical pharmacology
99:18–30.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26462575</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gokmen-Polar Y, Toroni RA, Hocevar BA, Badve S, Zhao Q, Shen C, Bruckheimer E, Kinch MS and Miller KD (2011) Dual targeting of EphA2 and ER restores tamoxifen sensitivity in ER/EphA2-positive breast cancer. Breast cancer research and treatment
127:375–384.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20602165</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goldgur Y, Susi P, Karelehto E, Sanmark H, Lamminmaki U, Oricchio E, Wendel HG, Nikolov DB and Himanen JP (2014) Generation and characterization of a single-chain anti-EphA2 antibody. Growth factors
32:214–222.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4335687</ArticleId>
            <ArticleId IdType="pubmed">25494541</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gong J, Korner R, Gaitanos L and Klein R (2016) Exosomes mediate cell contact-independent ephrin-Eph signaling during axon guidance. The Journal of cell biology
214:35–44.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4932373</ArticleId>
            <ArticleId IdType="pubmed">27354374</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gymrek M and Erlich Y (2011) Using DNA sequencers as stethoscopes. Genome medicine
3:73.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3308028</ArticleId>
            <ArticleId IdType="pubmed">22103962</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ha KD, Bidlingmaier SM, Zhang Y, Su Y and Liu B (2014) High-content analysis of antibody phage-display library selection outputs identifies tumor selective macropinocytosis-dependent rapidly internalizing antibodies. Molecular &amp; cellular proteomics : MCP
13:3320–3331.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4256486</ArticleId>
            <ArticleId IdType="pubmed">25149096</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hagemeyer CE, von Zur Muhlen C, von Elverfeldt D and Peter K (2009) Single-chain antibodies as diagnostic tools and therapeutic agents. Thrombosis and haemostasis
101:1012–1019.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19492141</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Halpin K, Hyatt AD, Fogarty R, Middleton D, Bingham J, Epstein JH, Rahman SA, Hughes T, Smith C, Field HE, Daszak P and The H (2011) Pteropid Bats are Confirmed as the Reservoir Hosts of Henipaviruses: A Comprehensive Experimental Study of Virus Transmission. Am J Trop Med Hyg
85:946–951.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3205647</ArticleId>
            <ArticleId IdType="pubmed">22049055</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hammond SA, Lutterbuese R, Roff S, Lutterbuese P, Schlereth B, Bruckheimer E, Kinch MS, Coats S, Baeuerle PA, Kufer P and Kiener PA (2007) Selective targeting and potent control of tumor growth using an EphA2/CD3-Bispecific single-chain antibody construct. Cancer research
67:3927–3935.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17440108</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Han X, Xu Y, Yang Y, Xi J, Tian W, Duggineni S, Huang Z and An J (2013) Discovery and characterization of a novel cyclic peptide that effectively inhibits ephrin binding to the EphA4 receptor and displays anti-angiogenesis activity. PloS one
8:e80183.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3827205</ArticleId>
            <ArticleId IdType="pubmed">24265799</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hasegawa J, Sue M, Yamato M, Ichikawa J, Ishida S, Shibutani T, Kitamura M, Wada T and Agatsuma T (2016) Novel anti-EPHA2 antibody, DS-8895a for cancer treatment. Cancer biology &amp; therapy
17:1158–1167.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5137487</ArticleId>
            <ArticleId IdType="pubmed">27653549</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hassan-Mohamed I, Giorgio C, Incerti M, Russo S, Pala D, Pasquale EB, Zanotti I, Vicini P, Barocelli E, Rivara S, Mor M, Lodola A and Tognolini M (2014) UniPR129 is a competitive small molecule Eph-ephrin antagonist blocking in vitro angiogenesis at low micromolar concentrations. British journal of pharmacology
171:5195–5208.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4294034</ArticleId>
            <ArticleId IdType="pubmed">24597515</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hattori M, Osterfield M and Flanagan JG (2000) Regulated cleavage of a contact-mediated axon repellent. Science
289:1360–1365.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10958785</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Heinzlmeir S, Lohse J, Treiber T, Kudlinzki D, Linhard V, Gande SL, Sreeramulu S, Saxena K, Liu X, Wilhelm M, Schwalbe H, Kuster B and Medard G (2017) Chemoproteomics-Aided Medicinal Chemistry for the Discovery of EPHA2 Inhibitors. ChemMedChem
12:999–1011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28544567</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Himanen JP (2012) Ectodomain structures of Eph receptors. Seminars in cell &amp; developmental biology
23:35–42.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22044883</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Himanen JP, Goldgur Y, Miao H, Myshkin E, Guo H, Buck M, Nguyen M, Rajashankar KR, Wang B and Nikolov DB (2009) Ligand recognition by A-class Eph receptors: crystal structures of the EphA2 ligand-binding domain and the EphA2/ephrin-A1 complex. EMBO Rep
10:722–728.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2727437</ArticleId>
            <ArticleId IdType="pubmed">19525919</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Himanen JP, Saha N and Nikolov DB (2007) Cell-cell signaling via Eph receptors and ephrins. Current opinion in cell biology
19:534–542.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3327877</ArticleId>
            <ArticleId IdType="pubmed">17928214</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Homaira N, Rahman M, Hossain MJ, Epstein JH, Sultana R, Khan MS, Podder G, Nahar K, Ahmed B, Gurley ES, Daszak P, Lipkin WI, Rollin PE, Comer JA, Ksiazek TG and Luby SP (2010) Nipah virus outbreak with person-to-person transmission in a district of Bangladesh, 2007. Epidemiol Infect
138:1630–1636.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20380769</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hood L, Balling R and Auffray C (2012) Revolutionizing medicine in the 21st century through systems approaches. Biotechnology journal
7:992–1001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3962497</ArticleId>
            <ArticleId IdType="pubmed">22815171</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Husa AM, Magic Z, Larsson M, Fornander T and Perez-Tenorio G (2016) EPH/ephrin profile and EPHB2 expression predicts patient survival in breast cancer. Oncotarget
7:21362–21380.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5008291</ArticleId>
            <ArticleId IdType="pubmed">26870995</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ieguchi K, Tomita T, Omori T, Komatsu A, Deguchi A, Masuda J, Duffy SL, Coulthard MG, Boyd A and Maru Y (2014) ADAM12-cleaved ephrin-A1 contributes to lung metastasis. Oncogene
33:2179–2190.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23686306</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Janes PW, Nievergall E and Lackmann M (2012) Concepts and consequences of Eph receptor clustering. Seminars in cell &amp; developmental biology
23:43–50.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22261642</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Janes PW, Saha N, Barton WA, Kolev MV, Wimmer-Kleikamp SH, Nievergall E, Blobel CP, Himanen JP, Lackmann M and Nikolov DB (2005) Adam meets Eph: an ADAM substrate recognition module acts as a molecular switch for ephrin cleavage in trans. Cell
123:291–304.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16239146</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Janes PW, Slape CI, Farnsworth RH, Atapattu L, Scott AM and Vail ME (2014) EphA3 biology and cancer. Growth factors
32:176–189.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25391995</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ji YJ, Hwang YS, Mood K, Cho HJ, Lee HS, Winterbottom E, Cousin H and Daar IO (2014) EphrinB2 affects apical constriction in Xenopus embryos and is regulated by ADAM10 and flotillin-1. Nature communications
5:3516.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4120273</ArticleId>
            <ArticleId IdType="pubmed">24662724</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jin L, Wang W and Fang G (2014) Targeting protein-protein interaction by small molecules. Annual review of pharmacology and toxicology
54:435–456.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24160698</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kaplan N, Ventrella R, Peng H, Pal-Ghosh S, Arvanitis C, Rappoport JZ, Mitchell BJ, Stepp MA, Lavker RM and Getsios S (2018) EphA2/Ephrin-A1 Mediate Corneal Epithelial Cell Compartmentalization via ADAM10 Regulation of EGFR Signaling. Invest Ophthalmol Vis Sci
59:393–406.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5774870</ArticleId>
            <ArticleId IdType="pubmed">29351356</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Koolpe M, Dail M and Pasquale EB (2002) An ephrin mimetic peptide that selectively targets the EphA2 receptor. The Journal of biological chemistry
277:46974–46979.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12351647</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Krasnoperov V, Kumar SR, Ley E, Li X, Scehnet J, Liu R, Zozulya S and Gill PS (2010) Novel EphB4 monoclonal antibodies modulate angiogenesis and inhibit tumor growth. The American journal of pathology
176:2029–2038.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2843490</ArticleId>
            <ArticleId IdType="pubmed">20133814</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kung A, Chen YC, Schimpl M, Ni F, Zhu J, Turner M, Molina H, Overman R and Zhang C (2016) Development of Specific, Irreversible Inhibitors for a Receptor Tyrosine Kinase EphB3. Journal of the American Chemical Society.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7476666</ArticleId>
            <ArticleId IdType="pubmed">27478969</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lagares D, Ghassemi-Kakroodi P, Tremblay C, Santos A, Probst CK, Franklin A, Santos DM, Grasberger P, Ahluwalia N, Montesi SB, Shea BS, Black KE, Knipe R, Blati M, Baron M, Wu B, Fahmi H, Gandhi R, Pardo A, Selman M, Wu J, Pelletier JP, Martel-Pelletier J, Tager AM and Kapoor M (2017) ADAM10-mediated ephrin-B2 shedding promotes myofibroblast activation and organ fibrosis. Nature medicine
23:1405–1415.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5720906</ArticleId>
            <ArticleId IdType="pubmed">29058717</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lamberto I, Lechtenberg BC, Olson EJ, Mace PD, Dawson PE, Riedl SJ and Pasquale EB (2014) Development and structural analysis of a nanomolar cyclic peptide antagonist for the EphA4 receptor. ACS chemical biology
9:2787–2795.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4273976</ArticleId>
            <ArticleId IdType="pubmed">25268696</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lamminmaki U, Nikolov D and Himanen J (2015) Eph Receptors as Drug Targets: Single-Chain Antibodies and Beyond. Current drug targets
16:1021–1030.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26028047</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Landen CN Jr., Lu C, Han LY, Coffman KT, Bruckheimer E, Halder J, Mangala LS, Merritt WM, Lin YG, Gao C, Schmandt R, Kamat AA, Li Y, Thaker P, Gershenson DM, Parikh NU, Gallick GE, Kinch MS and Sood AK (2006) Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer. Journal of the National Cancer Institute
98:1558–1570.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17077358</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee B, Pernet O, Ahmed AA, Zeltina A, Beaty SM and Bowden TA (2015) Molecular recognition of human ephrinB2 cell surface receptor by an emergent African henipavirus. Proc Natl Acad Sci U S A
112:E2156–2165.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4418902</ArticleId>
            <ArticleId IdType="pubmed">25825759</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lendeckel U, Kohl J, Arndt M, Carl-McGrath S, Donat H and Rocken C (2005) Increased expression of ADAM family members in human breast cancer and breast cancer cell lines. Journal of cancer research and clinical oncology
131:41–48.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15565459</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Levy GG, Motto DG and Ginsburg D (2005) ADAMTS13 turns 3. Blood
106:11–17.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15774620</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li D, Liu S, Liu R, Park R, Hughes L, Krasnoperov V, Gill PS, Li Z, Shan H and Conti PS (2013) Targeting the EphB4 receptor for cancer diagnosis and therapy monitoring. Mol Pharm
10:329–336.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3540204</ArticleId>
            <ArticleId IdType="pubmed">23211050</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lin KT, Sloniowski S, Ethell DW and Ethell IM (2008) Ephrin-B2-induced cleavage of EphB2 receptor is mediated by matrix metalloproteinases to trigger cell repulsion. The Journal of biological chemistry
283:28969–28979.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2570862</ArticleId>
            <ArticleId IdType="pubmed">18713744</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lisabeth EM, Falivelli G and Pasquale EB (2013) Eph receptor signaling and ephrins. Cold Spring Harbor perspectives in biology
5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3753714</ArticleId>
            <ArticleId IdType="pubmed">24003208</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu Z, Tao Z, Zhang Q, Wan S, Zhang F, Zhang Y, Wu G and Wang J (2018) YSA-conjugated mesoporous silica nanoparticles effectively target EphA2-overexpressing breast cancer cells. Cancer chemotherapy and pharmacology.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29392452</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lodola A, Giorgio C, Incerti M, Zanotti I and Tognolini M (2017) Targeting Eph/ephrin system in cancer therapy. European journal of medicinal chemistry
142:152–162.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28780190</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mao W, Luis E, Ross S, Silva J, Tan C, Crowley C, Chui C, Franz G, Senter P, Koeppen H and Polakis P (2004) EphB2 as a therapeutic antibody drug target for the treatment of colorectal cancer. Cancer research
64:781–788.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14871799</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Merchant AA, Jorapur A, McManus A, Liu R, Krasnoperov V, Chaudhry P, Singh M, Harton L, Agajanian M, Kim M, Triche TJ Jr., Druker BJ, Tyner JW and Gill PS (2017) EPHB4 is a therapeutic target in AML and promotes leukemia cell survival via AKT. Blood Adv
1:1635–1644.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5728330</ArticleId>
            <ArticleId IdType="pubmed">29296810</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mercurio FA and Leone M (2016) The Sam Domain of EphA2 Receptor and its Relevance to Cancer: A Novel Challenge for Drug Discovery?
Curr Med Chem
23:4718–4734.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27804871</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mercurio FA, Marasco D, Di Natale C, Pirone L, Costantini S, Pedone EM and Leone M (2016) Targeting EphA2-Sam and Its Interactome: Design and Evaluation of Helical Peptides Enriched in Charged Residues. Chembiochem
17:2179–2188.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27763725</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Micewicz ED, Jung CL, Schaue D, Luong H, McBride WH and Ruchala P (2011) Small Azurin Derived Peptide Targets Ephrin Receptors for Radiotherapy. Int J Pept Res Ther
17:247–257.</Citation>
        </Reference>
        <Reference>
          <Citation>Mohamed IH, Giorgio C, Bruni R, Flammini L, Barocelli E, Rossi D, Domenichini G, Poli F and Tognolini M (2011) Polyphenol rich botanicals used as food supplements interfere with EphA2-ephrinA1 system. Pharmacological research
64:464–470.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21742039</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moss ML and Lambert MH (2002) Shedding of membrane proteins by ADAM family proteases. Essays in biochemistry
38:141–153.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12463167</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Murai KK, Nguyen LN, Irie F, Yamaguchi Y and Pasquale EB (2003) Control of hippocampal dendritic spine morphology through ephrin-A3/EphA4 signaling. Nature neuroscience
6:153–160.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12496762</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nero TL, Morton CJ, Holien JK, Wielens J and Parker MW (2014) Oncogenic protein interfaces: small molecules, big challenges. Nature reviews Cancer
14:248–262.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24622521</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nievergall E, Lackmann M and Janes PW (2012) Eph-dependent cell-cell adhesion and segregation in development and cancer. Cell Mol Life Sci
69:1813–1842.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22204021</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nikolov DB, Xu K and Himanen JP (2013) Eph/ephrin recognition and the role of Eph/ephrin clusters in signaling initiation. Biochimica et biophysica acta
1834:2160–2165.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3777820</ArticleId>
            <ArticleId IdType="pubmed">23628727</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nikolov DB, Xu K and Himanen JP (2014) Homotypic receptor-receptor interactions regulating Eph signaling. Cell adhesion &amp; migration
8:360–365.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4594565</ArticleId>
            <ArticleId IdType="pubmed">25530219</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Noberini R, De SK, Zhang Z, Wu B, Raveendra-Panickar D, Chen V, Vazquez J, Qin H, Song J, Cosford ND, Pellecchia M and Pasquale EB (2011) A disalicylic acid-furanyl derivative inhibits ephrin binding to a subset of Eph receptors. Chemical biology &amp; drug design
78:667–678.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3196665</ArticleId>
            <ArticleId IdType="pubmed">21791013</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Noberini R, Koolpe M, Lamberto I and Pasquale EB (2012a) Inhibition of Eph receptor-ephrin ligand interaction by tea polyphenols. Pharmacological research
66:363–373.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3677025</ArticleId>
            <ArticleId IdType="pubmed">22750215</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Noberini R, Koolpe M, Peddibhotla S, Dahl R, Su Y, Cosford ND, Roth GP and Pasquale EB (2008) Small molecules can selectively inhibit ephrin binding to the EphA4 and EphA2 receptors. The Journal of biological chemistry
283:29461–29472.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2570887</ArticleId>
            <ArticleId IdType="pubmed">18728010</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Noberini R, Lamberto I and Pasquale EB (2012b) Targeting Eph receptors with peptides and small molecules: progress and challenges. Seminars in cell &amp; developmental biology
23:51–57.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3319464</ArticleId>
            <ArticleId IdType="pubmed">22044885</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Olson EJ, Lechtenberg BC, Zhao C, Rubio de la Torre E, Lamberto I, Riedl SJ, Dawson PE and Pasquale EB (2016) Modifications of a Nanomolar Cyclic Peptide Antagonist for the EphA4 Receptor To Achieve High Plasma Stability. ACS medicinal chemistry letters
7:841–846.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5018863</ArticleId>
            <ArticleId IdType="pubmed">27660688</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ong KC and Wong KT (2015) Henipavirus Encephalitis: Recent Developments and Advances. Brain pathology
25:605–613.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7161744</ArticleId>
            <ArticleId IdType="pubmed">26276024</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oricchio E, Nanjangud G, Wolfe AL, Schatz JH, Mavrakis KJ, Jiang M, Liu X, Bruno J, Heguy A, Olshen AB, Socci ND, Teruya-Feldstein J, Weis-Garcia F, Tam W, Shaknovich R, Melnick A, Himanen JP, Chaganti RS and Wendel HG (2011) The Eph-receptor A7 is a soluble tumor suppressor for follicular lymphoma. Cell
147:554–564.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3208379</ArticleId>
            <ArticleId IdType="pubmed">22036564</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pala D, Castelli R, Incerti M, Russo S, Tognolini M, Giorgio C, Hassan-Mohamed I, Zanotti I, Vacondio F, Rivara S, Mor M and Lodola A (2014) Combining ligand- and structure-based approaches for the discovery of new inhibitors of the EPHA2-ephrin-A1 interaction. Journal of chemical Information and modeling
54:2621–2626.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25289483</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pasquale EB (2005) Eph receptor signalling casts a wide net on cell behaviour. Nature reviews Molecular cell biology
6:462–475.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15928710</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Patel K, Doddapaneni R, Sekar V, Chowdhury N and Singh M (2016) Combination Approach of YSA Peptide Anchored Docetaxel Stealth Liposomes with Oral Antifibrotic Agent for the Treatment of Lung Cancer. Mol Pharm
13:2049–2058.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5730456</ArticleId>
            <ArticleId IdType="pubmed">27070720</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pegg CL, Cooper LT, Zhao J, Gerometta M, Smith FM, Yeh M, Bartlett PF, Gorman JJ and Boyd AW (2017) Glycoengineering of EphA4 Fc leads to a unique, long-acting and broad spectrum, Eph receptor therapeutic antagonist. Sci Rep
7:6519.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5529513</ArticleId>
            <ArticleId IdType="pubmed">28747680</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Petty A, Idippily N, Bobba V, Geldenhuys WJ, Zhong B, Su B and Wang B (2018) Design and synthesis of small molecule agonists of EphA2 receptor. European journal of medicinal chemistry
143:1261–1276.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5752149</ArticleId>
            <ArticleId IdType="pubmed">29128116</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Petty A, Myshkin E, Qin H, Guo H, Miao H, Tochtrop GP, Hsieh JT, Page P, Liu L, Lindner DJ, Acharya C, MacKerell AD Jr., Ficker E, Song J and Wang B (2012) A small molecule agonist of EphA2 receptor tyrosine kinase inhibits tumor cell migration in vitro and prostate cancer metastasis in vivo. PloS one
7:e42120.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3419725</ArticleId>
            <ArticleId IdType="pubmed">22916121</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Poliakov A, Cotrina M and Wilkinson DG (2004) Diverse roles of eph receptors and ephrins in the regulation of cell migration and tissue assembly. Developmental cell
7:465–480.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15469835</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Porotto M, Carta P, Deng Y, Kellogg GE, Whitt M, Lu M, Mungall BA and Moscona A (2007) Molecular determinants of antiviral potency of paramyxovirus entry inhibitors. Journal of virology
81:10567–10574.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2045485</ArticleId>
            <ArticleId IdType="pubmed">17652384</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rahman MA, Hossain MJ, Sultana S, Homaira N, Khan SU, Rahman M, Gurley ES, Rollin PE, Lo MK, Comer JA, Lowe L, Rota PA, Ksiazek TG, Kenah E, Sharker Y and Luby SP (2011) Date Palm Sap Linked to Nipah Virus Outbreak in Bangladesh, 2008. Vector Borne Zoonotic Dis.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21923274</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reddy P, Slack JL, Davis R, Cerretti DP, Kozlosky CJ, Blanton RA, Shows D, Peschon JJ and Black RA (2000) Functional analysis of the domain structure of tumor necrosis factor-alpha converting enzyme. The Journal of biological chemistry
275:14608–14614.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10799547</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Riedl SJ and Pasquale EB (2015) Targeting the Eph System with Peptides and Peptide Conjugates. Current drug targets
16:1031–1047.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4861043</ArticleId>
            <ArticleId IdType="pubmed">26212263</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Robberecht W and Philips T (2013) The changing scene of amyotrophic lateral sclerosis. Nature reviews Neuroscience
14:248–264.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23463272</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Saftig P and Reiss K (2011) The "A Disintegrin And Metalloproteases" ADAM10 and ADAM17: novel drug targets with therapeutic potential?
European journal of cell biology
90:527–535.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21194787</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Salem AF, Wang S, Billet S, Chen JF, Udompholkul P, Gambini L, Baggio C, Tseng HR, Posadas EM, Bhowmick NA and Pellecchia M (2018a) A potent EphA2 agonistic peptide-drug conjugate reduces circulating cancer cells and metastases in breast cancer models. J Med Chem.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5907794</ArticleId>
            <ArticleId IdType="pubmed">29470068</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Salem AF, Wang S, Billet S, Chen JF, Udompholkul P, Gambini L, Baggio C, Tseng HR, Posadas EM, Bhowmick NA and Pellecchia M (2018b) Reduction of Circulating Cancer Cells and Metastases in Breast- Cancer Models by a Potent EphA2-Agonistic Peptide-Drug Conjugate. J Med Chem
61:2052–2061.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5907794</ArticleId>
            <ArticleId IdType="pubmed">29470068</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Salgia R, Kulkarni P and Gill PS (2018) EphB4: A promising target for upper aerodigestive malignancies. Biochimica et biophysica acta
1869:128–137.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5955724</ArticleId>
            <ArticleId IdType="pubmed">29369779</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shi S, Liu J, Joshi SB, Krasnoperov V, Gill P, Middaugh CR and Volkin DB (2012) Biophysical characterization and stabilization of the recombinant albumin fusion protein sEphB4-HSA. J Pharm Sci
101:1969–1984.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22411527</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shi X, Hapiak V, Zheng J, Muller-Greven J, Bowman D, Lingerak R, Buck M, Wang BC and Smith AW (2017) A role of the SAM domain in EphA2 receptor activation. Sci Rep
7:45084.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5364462</ArticleId>
            <ArticleId IdType="pubmed">28338017</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sirintrapun SJ, Zehir A, Syed A, Gao J, Schultz N and Cheng DT (2015) Translational Bioinformatics and Clinical Research (Biomedical) Informatics. Surgical pathology clinics
8:269–288.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26065800</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Skotland T, Iversen TG, Torgersen ML and Sandvig K (2015) Cell-penetrating peptides: possibilities and challenges for drug delivery in vitro and in vivo. Molecules
20:13313–13323.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6332435</ArticleId>
            <ArticleId IdType="pubmed">26205056</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Solanas G, Cortina C, Sevillano M and Batlle E (2011) Cleavage of E-cadherin by ADAM10 mediates epithelial cell sorting downstream of EphB signalling. Nature cell biology
13:1100–1107.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21804545</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Spanevello MD, Tajouri SI, Mirciov C, Kurniawan N, Pearse MJ, Fabri LJ, Owczarek CM, Hardy MP, Bradford RA, Ramunno ML, Turnley AM, Ruitenberg MJ, Boyd AW and Bartlett PF (2013) Acute delivery of EphA4-Fc improves functional recovery after contusive spinal cord injury in rats. J Neurotrauma
30:1023–1034.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3689926</ArticleId>
            <ArticleId IdType="pubmed">23557244</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Steffen DL, Xu K, Nikolov DB and Broder CC (2012) Henipavirus mediated membrane fusion, virus entry and targeted therapeutics. Viruses
4:280–308.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3315217</ArticleId>
            <ArticleId IdType="pubmed">22470837</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stewart CR, Deffrasnes C, Foo CH, Bean AGD and Wang LF (2017) A Functional Genomics Approach to Henipavirus Research: The Role of Nuclear Proteins, MicroRNAs and Immune Regulators in Infection and Disease. Current topics in microbiology and immunology.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7122743</ArticleId>
            <ArticleId IdType="pubmed">28674944</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Swords RT, Greenberg PL, Wei AH, Durrant S, Advani AS, Hertzberg MS, Lewis ID, Rivera G, Gratzinger D, Fan AC, Felsher DW, Cortes JE, Watts JM, Yarranton GT, Walling JM and Lancet JE (2016) KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study. Leuk Res
50:123–131.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27736729</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Takano H, Nakamura T, Tsuchikawa T, Kushibiki T, Hontani K, Inoko K, Takahashi M, Sato S, Abe H, Takeuchi S, Sato N, Hiraoka K, Nishihara H, Shichinohe T and Hirano S (2015) Inhibition of Eph receptor A4 by 2,5-dimethylpyrrolyl benzoic acid suppresses human pancreatic cancer growing orthotopically in nude mice. Oncotarget
6:41063–41076.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4747390</ArticleId>
            <ArticleId IdType="pubmed">26516928</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Taki S, Kamada H, Inoue M, Nagano K, Mukai Y, Higashisaka K, Yoshioka Y, Tsutsumi Y and Tsunoda S (2015) A Novel Bispecific Antibody against Human CD3 and Ephrin Receptor A10 for Breast Cancer Therapy. PloS one
10:e0144712.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4682974</ArticleId>
            <ArticleId IdType="pubmed">26678395</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tang FY, Chiang EP and Shih CJ (2007) Green tea catechin inhibits ephrin-A1-mediated cell migration and angiogenesis of human umbilical vein endothelial cells. The Journal of nutritional biochemistry
18:391–399.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17049832</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Taylor H, Campbell J and Nobes CD (2017) Ephs and ephrins. Curr Biol
27:R90–R95.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28171762</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tognolini M, Giorgio C, Hassan Mohamed I, Barocelli E, Calani L, Reynaud E, Dangles O, Borges G, Crozier A, Brighenti F and Del Rio D (2012) Perturbation of the EphA2-EphrinA1 system in human prostate cancer cells by colonic (poly)phenol catabolites. Journal of agricultural and food chemistry
60:8877–8884.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22409255</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tognolini M, Incerti M and Lodola A (2014) Are we using the right pharmacological tools to target EphA4?
ACS chemical neuroscience
5:1146–1147.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25405504</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tognolini M and Lodola A (2015) Targeting the Eph-ephrin System with Protein-Protein Interaction (PPI) Inhibitors. Current drug targets
16:1048–1056.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26302794</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Truitt L and Freywald A (2011) Dancing with the dead: Eph receptors and their kinase-null partners. Biochemistry and cell biology = Biochimie et biologie cellulaire
89:115–129.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21455264</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Turk B (2006) Targeting proteases: successes, failures and future prospects. Nature reviews Drug discovery
5:785–799.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16955069</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Unzue A, Lafleur K, Zhao H, Zhou T, Dong J, Kolb P, Liebl J, Zahler S, Caflisch A and Nevado C (2016) Three stories on Eph kinase inhibitors: From in silico discovery to in vivo validation. European journal of medicinal chemistry
112:347–366.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26907157</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vail ME, Murone C, Tan A, Hii L, Abebe D, Janes PW, Lee FT, Baer M, Palath V, Bebbington C, Yarranton G, Llerena C, Garic S, Abramson D, Cartwright G, Scott AM and Lackmann M (2014) Targeting EphA3 inhibits cancer growth by disrupting the tumor stromal microenvironment. Cancer research
74:4470–4481.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25125683</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vargas LM, Leal N, Estrada LD, Gonzalez A, Serrano F, Araya K, Gysling K, Inestrosa NC, Pasquale EB and Alvarez AR (2014) EphA4 activation of c-Abl mediates synaptic loss and LTP blockade caused by amyloid-beta oligomers. PloS one
9:e92309.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3962387</ArticleId>
            <ArticleId IdType="pubmed">24658113</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vearing C, Lee FT, Wimmer-Kleikamp S, Spirkoska V, To C, Stylianou C, Spanevello M, Brechbiel M, Boyd AW, Scott AM and Lackmann M (2005) Concurrent binding of anti-EphA3 antibody and ephrin-A5 amplifies EphA3 signaling and downstream responses: potential as EphA3-specific tumor-targeting reagents. Cancer research
65:6745–6754.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16061656</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang L-F, Mackenzie JS and Broder CC (2013) Henipaviruses, in Fields Virology (Knipe DM and Howley PM eds) pp 1070–1085, Lippincott Williams &amp; Wilkins, Philadelphia.</Citation>
        </Reference>
        <Reference>
          <Citation>Wang Y, Li Q, Zheng Y, Li G and Liu W (2016) Systematic biochemical characterization of the SAM domains in Eph receptor family from Mus Musculus. Biochemical and biophysical research communications
473:1281–1287.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27086853</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weatherman S, Feldmann H and de Wit E (2017) Transmission of henipaviruses. Current opinion in virology
28:7–11.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5835161</ArticleId>
            <ArticleId IdType="pubmed">29035743</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wei S, Xu G, Bridges LC, Williams P, White JM and DeSimone DW (2010) ADAM13 induces cranial neural crest by cleaving class B Ephrins and regulating Wnt signaling. Developmental cell
19:345–352.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2951023</ArticleId>
            <ArticleId IdType="pubmed">20708595</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wimmer-Kleikamp SH, Janes PW, Squire A, Bastiaens PI and Lackmann M (2004) Recruitment of Eph receptors into signaling clusters does not require ephrin contact. The Journal of cell biology
164:661–666.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2172175</ArticleId>
            <ArticleId IdType="pubmed">14993233</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wimmer-Kleikamp SH and Lackmann M (2005) Eph-modulated cell morphology, adhesion and motility in carcinogenesis. IUBMB life
57:421–431.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16012051</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu B, Barile E, De SK, Wei J, Purves A and Pellecchia M (2015a) High-Throughput Screening by Nuclear Magnetic Resonance (HTS by NMR) for the Identification of PPIs Antagonists. Curr Top Med Chem
15:2032–2042.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4545611</ArticleId>
            <ArticleId IdType="pubmed">25986689</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu B, De SK, Kulinich A, Salem AF, Koeppen J, Wang R, Barile E, Wang S, Zhang D, Ethell I and Pellecchia M (2017) Potent and Selective EphA4 Agonists for the Treatment of ALS. Cell Chem Biol
24:293–305.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6522132</ArticleId>
            <ArticleId IdType="pubmed">28196613</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu B, Wang S, De SK, Barile E, Quinn BA, Zharkikh I, Purves A, Stebbins JL, Oshima RG, Fisher PB and Pellecchia M (2015b) Design and Characterization of Novel EphA2 Agonists for Targeted Delivery of Chemotherapy to Cancer Cells. Chem Biol
22:876–887.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4515144</ArticleId>
            <ArticleId IdType="pubmed">26165155</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xiong C, Huang M, Zhang R, Song S, Lu W, Flores L 2nd, Gelovani J and Li C (2011) In vivo small-animal PET/CT of EphB4 receptors using 64Cu-labeled peptide. J Nucl Med
52:241–248.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21233177</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu D, Bum-Erdene K, Si Y, Zhou D, Ghozayel MK and Meroueh SO (2017) Mimicking Intermolecular Interactions of Tight Protein-Protein Complexes for Small-Molecule Antagonists. ChemMedChem
12:1794–1809.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6067920</ArticleId>
            <ArticleId IdType="pubmed">28960868</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu D, Jalal SI, Sledge GW and Meroueh SO (2016) Small-molecule binding sites to explore protein-protein interactions in the cancer proteome. Mol Biosyst
12:3067–3087.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5030169</ArticleId>
            <ArticleId IdType="pubmed">27452673</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu K, Broder CC and Nikolov DB (2012a) Ephrin-B2 and ephrin-B3 as functional henipavirus receptors. Seminars in cell &amp; developmental biology
23:116–123.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3327611</ArticleId>
            <ArticleId IdType="pubmed">22227101</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu K, Chan YP, Rajashankar KR, Khetawat D, Yan L, Kolev MV, Broder CC and Nikolov DB (2012b) New insights into the Hendra virus attachment and entry process from structures of the virus G glycoprotein and its complex with Ephrin-B2. PloS one
7:e48742.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3489827</ArticleId>
            <ArticleId IdType="pubmed">23144952</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu K, Rajashankar KR, Chan YP, Himanen JP, Broder CC and Nikolov DB (2008) Host cell recognition by the henipaviruses: crystal structures of the Nipah G attachment glycoprotein and its complex with ephrin-B3. Proc Natl Acad Sci U S A
105:9953–9958.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2474567</ArticleId>
            <ArticleId IdType="pubmed">18632560</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu K, Rockx B, Xie Y, DeBuysscher BL, Fusco DL, Zhu Z, Chan YP, Luu T, Cer R, Feldmann H, Mokashi V, Dimitrov DS, Bishop-Lilly KA, Broder CC and Nikolov DB (2013a) Crystal structure of the Hendra virus attachment G glycoprotein bound to a potent cross-reactive neutralizing human monoclonal antibody. PLoS Pathog
in press.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3795035</ArticleId>
            <ArticleId IdType="pubmed">24130486</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu K, Tzvetkova-Robev D, Xu Y, Goldgur Y, Chan YP, Himanen JP and Nikolov DB (2013b) Insights into Eph receptor tyrosine kinase activation from crystal structures of the EphA4 ectodomain and its complex with ephrin-A5. Proc Natl Acad Sci U S A
110:14634–14639.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3767517</ArticleId>
            <ArticleId IdType="pubmed">23959867</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>You J, Zhang R, Xiong C, Zhong M, Melancon M, Gupta S, Nick AM, Sood AK and Li C (2012) Effective photothermal chemotherapy using doxorubicin-loaded gold nanospheres that target EphB4 receptors in tumors. Cancer research
72:4777–4786.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3445780</ArticleId>
            <ArticleId IdType="pubmed">22865457</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zang X, Ding H, Zhao X, Li X, Du Z, Hu H, Qiao M, Chen D, Deng Y and Zhao X (2016) Anti-EphA10 antibody-conjugated pH-sensitive liposomes for specific intracellular delivery of siRNA. Int J Nanomedicine
11:3951–3967.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4993279</ArticleId>
            <ArticleId IdType="pubmed">27574425</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhu Z, Bossart KN, Bishop KA, Crameri G, Dimitrov AS, McEachern JA, Feng Y, Middleton D, Wang LF, Broder CC and Dimitrov DS (2008) Exceptionally potent cross-reactive neutralization of Nipah and Hendra viruses by a human monoclonal antibody. The Journal of infectious diseases
197:846–853.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7199872</ArticleId>
            <ArticleId IdType="pubmed">18271743</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhuang G, Brantley-Sieders DM, Vaught D, Yu J, Xie L, Wells S, Jackson D, Muraoka-Cook R, Arteaga C and Chen J (2010) Elevation of receptor tyrosine kinase EphA2 mediates resistance to trastuzumab therapy. Cancer research
70:299–308.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3859619</ArticleId>
            <ArticleId IdType="pubmed">20028874</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
